Instructions de recherche:
* Filter the ENTIRE resource library: Choose a OR a to sort all resources.
* Choose Search Items : to filter one collection or perform complex queries.
* Choose Browse by Topic to search by one or more Topics.
Parcourir les contenus (92 total)
-
Créateur: NIH
Sujet: Infection Control
Type d'élément: Lien hypertexte
Date de la dernière mise à jour: 2020-05-04
Description: This is a phase I, open-label, dose ranging clinical trial in males and non-pregnant females, starting at 18 years of age, inclusive, who are in good health and meet all eligibility criteria. This clinical trial is designed to assess the safety,… -
Créateur: National Institute of Allergy and Infectious Diseases (NIAID)
Sujet: Research
Type d'élément: Lien hypertexte
Date de la dernière mise à jour: 2020-03-30
Description: This is a phase I, open-label, dose ranging clinical trial in males and non-pregnant females, 18 to 55 years of age, inclusive, who are in good health and meet all eligibility criteria. This clinical trial is designed to assess the safety,… -
Créateur: Barda, Noam, Noa Dagan, Yatir Ben-Shlomo, Eldad Kepten, Jacob Waxman, Reut Ohana, Miguel A. Hernán, Marc Lipsitch, Isaac Kohane, Doron Netzer, Ben Y. Reis, and Ran D. Balicer.
Sujet: Research
Type d'élément: Publication
Date de la dernière mise à jour: 2021-08-25
Description: Preapproval trials showed that messenger RNA (mRNA)–based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety profile, yet these trials were subject to size and patient-mix limitations. An evaluation of the… -
Créateur: Tapia, Milagritos D., Samba O. Sow, Birahim P. Ndiaye, Khardiata D. Mbaye, Aliou Thiongane, Cheikh T. Ndour, Souleymane Mboup, Julie A. Ake, Babajide Keshinro, Gideon A. Akintunde, Thompson N. Kinge, Guy Vernet, Jean Joel Bigna, Stephen Oguche,…
Sujet: Research
Type d'élément: Publication
Date de la dernière mise à jour: 2020-03-19
Description: The 2014 Zaire Ebola virus disease epidemic accelerated vaccine development for the virus. -
Créateur: Tapia, Milagritos D., Samba O. Sow, Khardiata D. Mbaye, Aliou Thiongane, Birahim P. Ndiaye, Cheikh T. Ndour, Souleymane Mboup, Babajide Keshinro, Thompson N. Kinge, Guy Vernet, Jean Joel Bigna, Stephen Oguche, Kwadwo A. Koram, Kwaku P. Asante,…
Sujet: Research
Type d'élément: Publication
Date de la dernière mise à jour: 2020-03-19
Description: During the large 2013–16 Ebola virus outbreak caused by the Zaire Ebola virus, about 20% of cases were reported in children. This study is the first, to our knowledge, to evaluate an Ebola vaccine in children younger than 6 years. -
Créateur: Wu, Zhiwei, Yaling Hu, Miao Xu, Zhen Chen, Wanqi Yang, Zhiwei Jiang, Minjie Li, Hui Jin, Guoliang Cui, Panpan Chen, Lei Wang, Guoqing Zhao, Yuzhu Ding, Yuliang Zhao, and Weidong Yin.
Sujet: Research
Type d'élément: Publication
Date de la dernière mise à jour: 2021-02-03
Description: A vaccine against COVID-19 is urgently needed for older adults, in whom morbidity and mortality due to the disease are increased. We aimed to assess the safety, tolerability, and immunogenicity of a candidate COVID-19 vaccine, CoronaVac, containing… -
Créateur: Zhang, Yanjun, Gang Zeng, Hongxing Pan, Changgui Li, Yaling Hu, Kai Chu, Weixiao Han, Zhen Chen, Rong Tang, Weidong Yin, Xin Chen, Yuansheng Hu, Xiaoyong Liu, Congbing Jiang, Jingxin Li, Minnan Yang, Yan Song, Xiangxi Wang, Qiang Gao, and Fengcai…
Sujet: Laboratory
Type d'élément: Publication
Date de la dernière mise à jour: 2020-11-17
Description: With the unprecedented morbidity and mortality associated with the COVID-19 pandemic, a vaccine against COVID-19 is urgently needed. We investigated CoronaVac (Sinovac Life Sciences, Beijing, China), an inactivated vaccine candidate against COVID-19,… -
Créateur: Poland, Gregory A., Inna G. Ovsyannikova, and Richard B. Kennedy.
Sujet: Laboratory
Type d'élément: Publication
Date de la dernière mise à jour: 2020-10-13
Description: Understanding immune responses to severe acute respiratory syndrome coronavirus 2 is crucial to understanding disease pathogenesis and the usefulness of bridge therapies, such as hyperimmune globulin and convalescent human plasma, and to developing… -
Créateur: Keehner, Jocelyn, Lucy E. Horton, Michael A. Pfeffer, Christopher A. Longhurst, Robert T. Schooley, Judith S. Currier, Shira R. Abeles, and Francesca J. Torriani.
Sujet: Research
Type d'élément: Publication
Date de la dernière mise à jour: 2021-03-23
Description: Data from phase 3 clinical trials of messenger RNA (mRNA) vaccines through November 2020 showed 94.1% efficacy for the prevention of symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection at 14 days after the second dose…Example only: NETEC provides this item for reference purposes but does not endorse its content. Newer versions may be in place at the providing institution.
-
Créateur: Wu, Kai, Anne P. Werner, Matthew Koch, Angela Choi, Elisabeth Narayanan, Guillaume B. E. Stewart-Jones, Tonya Colpitts, Hamilton Bennett, Seyhan Boyoglu-Barnum, Wei Shi, Juan I. Moliva, Nancy J. Sullivan, Barney S. Graham, Andrea Carfi, Kizzmekia S.…
Sujet: Research
Type d'élément: Publication
Date de la dernière mise à jour: 2021-02-17
Description: The mRNA-1273 vaccine against SARS-CoV-2 elicited high neutralizing-antibody titers in phase 1 trial participants and has been shown to be highly efficacious in preventing symptomatic Covid-19 disease and severe disease.